Volcano Announces OCT Activities at EuroPCR 2009
Volcano's Axsun Laser - At the Heart of OCT
SAN DIEGO and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC ), a leader in the development, manufacturing and sales of products for the diagnosis of coronary and peripheral artery disease, today highlights it...
Abbott Announces EuroPCR 2009 Activities
- New data to be presented on Abbott's market-leading XIENCE V(R) stent
- Educational information available on XIENCE PRIME(TM), Abbott's next-generation drug eluting stent in development
BARCELONA, Spain, May 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced the company...
Boston Scientific Announces Schedule for EuroPCR 2009
NATICK, Mass., May 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's events and news announcements at the annual EuroPCR
Scientific Program, which runs from May 19 to 22 in Barcelona, Spain.
"We are pleased to be announcing...
CorNova to Present at the Glimpse into the Future: Emerging Drug-Eluting Stents Symposium at EuroPCR 2009
S. Eric Ryan, M.D., Will Discuss the Valecor Platinum(TM) Coronary Stent System on the FiberHalo(TM) Balloon Angioplasty Catheter
BURLINGTON, Mass., May 14 /PRNewswire/ -- CorNova Inc. today announced S. Eric Ryan, M.D., the company's chairman and chief executive officer, will present the Val...
LightLab Imaging Introduces World's Highest Resolution OCT System for Intracoronary Imaging at EuroPCR 2009
Launch of C7XR(TM) FD-OCT Imaging System and Companion C7 Dragonfly(TM) Imaging Catheter Strengthen LightLab's Market Leadership
WESTFORD, Mass., May 14 /PRNewswire/ -- LightLab Imaging Inc., the pioneer and leader in the development of Optical Coherence Tomography (OCT) for vascular and othe...
PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008
FRANKLIN, Mass., May 12 /PRNewswire-FirstCall/ -- PLC Systems Inc.
(AMEX: PLC ), a company focused on innovative cardiac and vascular medical
device-based technologies, announced today that it will demonstrate its
RenalGuard System(TM) at EuroPCR, the annual meeting of the European
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
...y Consistent with Superior Results from Randomized Clinical Trials
BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at europcr
from an international, post-approval, single-arm study show that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstr...
SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
... narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual europcr
Scientific Program in Barcelona.
SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 trea...
XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
... the publication after presenting it at the
"I am very pleased to congratulate Dr. ...ll that need."
The paper and presentation at the europcr
meeting discussed the
previously released positive...s.
EuroIntervention is the official publication of europcr
and the European
Association of Percutaneous Cardi...
TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
...nd non-diabetic patients.
Analysis of the data was presented by David A. Cox, M.D., F.A.C.C., and
John M. Lasala, M.D., Ph.D., F.A.C.C., at the annual europcr
Program in Barcelona.
"The ARRIVE diabetic subset data demonstrated that the TAXUS Stent
mitigated the adverse effect of diabetes as a ri...
EuroPCR in Medical Technology
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies
BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented a...
PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009
Live Case Demonstrating RenalGuard To Be Presented
FRANKLIN, Mass., May 15 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard Sy...
Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
Randomized TRIAS HR Pilot Study Compares Genous, Boston Scientific's Taxus(R)
Other Presentations Focus on Real-World Use of Genous, Stent's Performance in Patients with AMI, Those Who Could Not Tolerate Dual-Antiplatelet Therapy
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
Company Will Host Webcast to Review Data Tuesday, May 13 at 1:00 p.m. EDT (7:00 p.m. CEST)
BARCELONA, Spain and MENLO PARK, Calif., May 13 /PRNewswire-FirstCall/
-- XTENT, Inc. (Nasdaq: XTNT ) today announced positive six-month follow-up
data from the CUSTOM III clin...
Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
Other Data Presentations to Focus on Use of Pro-Healing Stent with AMI Patients and Those Who Cannot Tolerate Dual-Antiplatelet Therapy
HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both
a randomized pilot study and the real-world registry use of OrbusNeich's
XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th
MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc.
(Nasdaq: XTNT ) today announced that six-month follow-up data from the
CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in
Boston Scientific Announces Schedule for EuroPcr 2007
Company to release broad range of clinical data on leading
drug-eluting stent portfolio
NATICK, Mass., May 15, 2007 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation today announced the schedule of the
Company's major events and press announcements at the annual Paris
Course on Revasculariza...
XTENT Announces Promising Six-Month Custom II Trial Data Presented
at EuroPCR Meeting
Trial Included One of the Most Challenging Patient Populations
Studied of Any Drug-Eluting Stent (DES) Clinical Trial
BARCELONA and MENLO PARK, Calif., May 22, 2007
/PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-month
follow-up data from the CUSTOM II clinical trial, which assessed
Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial
Results at EuroPCR 2007
BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principal
investigators for the COSTAR II (CObalt Chromium STent with
Antiproliferative for Restenosis) trial, the pivotal study for the
CoStar(R) cobalt chromium paclitaxel-eluting coronary stent,
presented today the clinical trial results of the stu...
Medtronic Announces Positive Nine-Month Results for Endeavor
Resolute Next Generation Drug-Eluting Stent at EuroPCR
BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian
Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on
Tuesday presented positive nine-month results from the Medtronic
RESOLUTE clinical trial at the EuroPCR
meeting in Barcelona, Spain,
with data showing a low number of adve...
EuroPCR in Biological Technology
InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today
the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute
Myocardial). The trial was designed to confirm the clinical feasibility,
safety and performance of MGuard when used during Primary PCI in STEMI
Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008
Company Pursues Strategy of Reducing Heart Attack Deaths by Shielding High-Risk Plaques in Coronary Arteries
DOYLESTOWN, Pa., May 8 /PRNewswire/ --- Prescient Medical, Inc., a
privately held medical device company dedicated to reducing deaths from
heart attacks, will present n...
SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
...t narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual europcr
Scientific Program in Barcelona.
SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 treated...
First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
...s with coronary artery disease."
Live patient case to be broadcast at europcr
Conference this week
On Wednesday, May 20, Dr. van der Ent will be pe...orming a live case with the combined catheter from the Thoraxcenter for the europcr
Conference taking place this week in Barcelona, Spain from May 19 - 22, 200...
Boston Scientific Welcomes Launch of Syntax Score Website
...YNTAX Score(TM), a novel angiographic tool used to measure the complexity of coronary artery disease. The Company made the announcement at the annual europcr
Scientific Program in Barcelona.
The SYNTAX Score was developed in connection with the SYNTAX trial, the first randomized, controlled clinical tr...
Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
...s. Over and Under(R) PCS was presented by Dr. Haim Danenberg, Head
of Interventional Cardiology Unit and the company's medical director, at
the annual europcr
meeting. Study was performed in phantom and porcine
coronaries. Over and Under(R) PCS appeared to be significantly superior in
deliverability in both ...
Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
... 2006. This announcement comes
just prior to Volcano's participation in the europcr
2008 Congress, to be
held in Barcelona, Spain, from May 12-15th. During the...xible than ever before.
Presence at EuroPCR08
Volcano's presence at the europcr
2008 Congress in Barcelona will
include live case transmissions with IVUS, ...
Biopure Announces 2008 First Quarter Financial Results
... Association of Interventional Cardiology. EIJ is a peer-reviewed
journal of interventional cardiovascular medicine and is the official
publication of europcr
and the European Association of Percutaneous
Cardiovascular Interventions (EAPCI).
The accepted manuscript reports on the Company's first pilot isch...